报价延迟最少15分钟:2025/07/18 16:30 EDT
盘后时段
|
||||
|
12.49 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.49
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.97/-2.93
|
|
企业价值
1.72B
|
| 资产负债 |
|
每股账面净值
0.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/18 16:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
